Modelling human haematopoietic stem cell commitment ex vivo identifies IL-33 as a regulator of megakaryopoiesis
Commitment events to specific blood lineages arise from single hematopoietic stem cells (HSCs) and are influenced by stress, inflammation and disease. However, the understanding of how such events are regulated in human haematopoiesis is limited by the lack of tractable in vitro models. In this study, we introduce a novel Early Progenitor Differentiation (EPD) assay to study the initial lineage…
A groundbreaking study has uncovered a new regulatory mechanism in human hematopoiesis, the process of blood cell formation. Researchers have developed a novel in vitro model, the Early Progenitor Differentiation (EPD) assay, to study the initial commitment of human 49+ hematopoietic stem cells (HSCs) to specific lineages. By employing single cell -omics and functional assays, the team revealed that IL-33 plays a crucial role in activating the MAPK pathway, promoting the commitment of HSCs to Megakaryocytic-Erythroid-Mast cell Progenitors and subsequent megakaryopoiesis.
This finding, published in the journal Nature, highlights the utility of the EPD model in identifying molecular regulators of human HSC differentiation and sheds light on a previously unknown role of IL-33 in hematopoiesis.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
